GCS 100 IV / Innoviva 
Welcome,         Profile    Billing    Logout  
 30 Diseases   1 Trial   1 Trial   30 News 
  • ||||||||||  GCS 100 IV / Innoviva
    Impact of Baseline Glucocorticoid Use on the Efficacy of Immunoradiotherapy in NSCLC Patients with Brain Metastases (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1412;    
    The propensity score matching proved that the group of high GCs use still had significant differences in median iPFS (5.23 months vs 8.93 months, p=0.023), median PFS (4.33 months vs 8.10 months, P=0.046) and median OS (7.47 months vs 14.63 months, P=0.033) comparing with the patients of median GCs use and low GCs use (Figure1). Conclusions : The application of GCs often increased in patients with NSCLC brain metastases receiving immunotherapy combined with intracranial radiotherapy and the baseline high dose GCs use (GCs?100mg) will reduce the efficacy of the combination therapy and impair the survival outcomes.
  • ||||||||||  GCS 100 IV / La Jolla Pharma
    Preclinical, Journal:  Effect of long-term chronic hyperhomocysteinemia on retinal structure and function in the cystathionine-β-synthase mutant mouse. (Pubmed Central) -  Feb 12, 2022   
    Immunohistochemistry revealed ∼5 RGCs/100 μm retinal length in both Cbs and WT mice at 20 months...We conclude that chronic, moderate Hhcy (at least due to deficiency of Cbs) is not accompanied by retinal structural/functional changes that differ significantly from age-matched WT littermates. Despite considerable evidence that severe Hhcy is toxic to retina, moderate Hhcy appears tolerated by retina suggesting compensatory cellular survival mechanisms.
  • ||||||||||  Review, Journal:  Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma. (Pubmed Central) -  Oct 22, 2021   
    Other agents restore PIs' efficacy through caspase-dependent tools, such as CDDO-Im, NOXA-inhibitors, FTY720, GCS-100, LBH589, a derivative of ellipticine, AT-101, KD5170, SMAC-mimetics, glutaminase-1 (GLS1)-inhibitors, and thenoyltrifluoroacetone. Each of these substances improved the efficacy rates when employed in combination with the most frequently used antimyeloma drugs.
  • ||||||||||  GCS 100 IV / La Jolla Pharma
    Trial completion, P2 data, Enrollment change, Trial primary completion date:  A Phase 2 Extension Study of Study GCS-100-CS-4002 (clinicaltrials.gov) -  Dec 27, 2016   
    P2,  N=92, Completed, 
    However, the 3-year DFS and 5-year OS rate in this trial were similar to several pivotal trials.Legal entity responsible for the study: Non-Political Organization: Hokkaido Gastrointestinal Cancer Study Group. Active, not recruiting --> Completed | N=116 --> 92 | Trial primary completion date: Dec 2015 --> May 2016
  • ||||||||||  GCS 100 IV / La Jolla Pharma
    P2 data, Trial primary completion date:  A Phase 2 Extension Study of Study GCS-100-CS-4002 (clinicaltrials.gov) -  Sep 25, 2015   
    P2,  N=116, Active, not recruiting, 
    Active, not recruiting --> Completed | N=116 --> 92 | Trial primary completion date: Dec 2015 --> May 2016 Trial primary completion date: Jun 2015 --> Dec 2015
  • ||||||||||  GCS 100 IV / La Jolla Pharma
    P2 data, Enrollment change, Trial withdrawal:  A Phase 2 Extension of Study GCS-100-CS-4003 (clinicaltrials.gov) -  Feb 7, 2015   
    P2,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2015 N=93 --> 0 | Active, not recruiting --> Withdrawn
  • ||||||||||  GCS 100 IV / La Jolla Pharma
    New P2 trial, P2 data:  A Phase 2 Extension of Study GCS-100-CS-4003 (clinicaltrials.gov) -  Jan 8, 2015   
    P2,  N=93, Active, not recruiting, 
  • ||||||||||  GCS 100 IV / La Jolla Pharma
    Trial completion:  Safety Study of GCS-100 to Treat Chronic Kidney Disease (clinicaltrials.gov) -  Jun 18, 2013   
    P1,  N=29, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed